Browse the evidence

Tirzepatide (a dual GIP/GLP-1 agonist) is better tolerated regarding GI side effects compared to semaglutide (a GLP-1 agonist), likely due to GIP receptor activation having anti-emetic properties.

If you struggle with stomach issues on Semaglutide (Ozempic/Wegovy), ask your doctor about Tirzepatide (Mounjaro/Zepbound). Clinical trials show it causes fewer GI side effects and fewer people stop taking it, possibly because of how it interacts with GIP receptors in the gut.

GLP-1 receptor agonists (GLP-1RAs) significantly reduce body weight, BMI, and waist circumference in patients with psychiatric disorders and obesity, with efficacy comparable to or slightly lower than that observed in non-psychiatric populations.

If you have a psychiatric condition and are overweight, GLP-1 medications (like semaglutide or liraglutide) are a proven, effective option for losing weight, even if you take other psychiatric meds. You will likely lose about 5 kg (11 lbs) on average, which is less than in people without mental health conditions, but still significant. Side effects like nausea are common but usually mild and don't cause most people to stop treatment. Discuss this with your doctor as a priority for metabolic health.

Most plant-based meat analogues on the market have insufficient protein quality or quantity compared to animal meat, and very few are fortified with essential micronutrients like Vitamin B12 or Iron.

Do not assume plant-based meats are nutritionally complete. Check labels for Vitamin B12 and Iron fortification, as only 12% of products include them. Also, verify protein quality; many analogues have lower digestible indispensable amino acid scores (DIAAS) than meat. If you eat these frequently, consider a B12 supplement and ensure you are getting enough total protein.

Higher intake of total fat, saturated fatty acids, monounsaturated fatty acids, and polyunsaturated fatty acids is associated with lower prevalence of covert brain infarcts and white matter hyperintensities, and higher cognitive scores (DSST).

Don't fear fat. This study found that people who ate more fat, including saturated, monounsaturated, and polyunsaturated fats, had less brain injury on MRI and better cognitive scores. Try incorporating more healthy fats into your diet, such as those found in nuts, seeds, and olive oil.

Among patients with severe obesity treated with semaglutide 2.4 mg/week, those with higher intuitive eating scores and lower anxiety/depression levels (Intuitive Eaters Group) achieve significantly greater weight loss than those with higher emotional distress and lower intuitive eating scores (Emotionally Driven Eaters Group).

If you are taking semaglutide for severe obesity, your mental health and eating mindset matter for your results. Patients with high emotional distress and lower intuitive eating skills tend to lose less weight than those with better emotional regulation and intuitive eating habits. To maximize your weight loss, consider integrating psychological support or intuitive eating strategies alongside your medication, as these factors significantly influence your trajectory.

In oncology patients, muscle-specific strength (MSS) estimated via anthropometry (body weight or calf circumference) or bioimpedance (BIA) provides a reliable alternative to DXA-derived MSS, enabling functional assessment in resource-limited settings.

For cancer patients or clinicians without access to DXA scanners, you can accurately estimate muscle quality by dividing handgrip strength by body weight or calf circumference. This method correlates very strongly with the gold standard DXA test, allowing for effective monitoring of sarcopenia and treatment response in routine clinical settings.

Administering semaglutide to US adults with type 2 diabetes who meet SUSTAIN-6 trial eligibility criteria prevents approximately 75,681 primary composite cardiovascular events annually.

If you have Type 2 Diabetes and meet specific risk criteria (age over 50 with heart/kidney issues, or over 60 with additional risk factors), asking your doctor about semaglutide could potentially prevent tens of thousands of major heart events in your demographic group annually. The medication is a weekly injection that has been shown to significantly lower the risk of heart attack, stroke, and cardiovascular death in clinical trials.

Treatment with the Epitomee shape-shifting hydrogel capsule combined with lifestyle intervention significantly improves health-related quality of life (HRQOL), specifically in Physical Function and total scores, compared to placebo in adults with overweight or obesity.

If you are overweight or have obesity (BMI 27-40) and struggle with portion control, this hydrogel capsule may help improve your quality of life and physical function more than lifestyle changes alone. You take one capsule with a large glass of water 30 minutes before your two main meals daily. It expands in your stomach to help you feel full sooner. This approach is particularly useful if you want to avoid medications or have contraindications to them. The benefits are most pronounced if you lose 10% or more of your body weight, but even modest loss improves physical function scores significantly.

Dietary capsinoids (9 mg/day) increase resting energy expenditure and brown adipose tissue density in healthy and overweight middle-aged adults.

Take 9 mg of capsinoids daily. This simple supplement has been shown in human trials to increase your resting energy expenditure and increase the amount of active brown fat, even in overweight individuals. It is a low-effort way to slightly boost your metabolic rate.

Caffeine (375 mg capsule or equivalent from coffee/tea) increases energy expenditure and brown adipose tissue activity in physically active humans.

Consume 375 mg of caffeine (or equivalent from coffee/tea) 30 minutes before activity. This has been shown to increase energy expenditure and activate brown fat, particularly in physically active men. It is a practical way to leverage a common substance for metabolic benefit.

Beta-3 adrenergic receptor agonists (e.g., mirabegron) increase brown adipose tissue activation, metabolic rate, and reduce blood glucose, but are limited by adverse cardiovascular effects.

Mirabegron increases brown fat and metabolism but causes high blood pressure and heart rate. It is not recommended for weight loss due to these cardiovascular risks.

GLP-1 receptor agonists (e.g., liraglutide, semaglutide) induce a weight loss plateau over time, suggesting that appetite suppression alone is insufficient for sustained weight management and highlighting the need for complementary thermogenic strategies.

If you are on a GLP-1 medication like semaglutide or liraglutide and your weight loss has stalled after the first year, this is a common physiological plateau, not a failure. The medication's appetite-suppressing effect has maxed out. To continue losing weight, you may need to add strategies that increase energy expenditure, such as exercise-induced thermogenesis or potentially future thermogenic medications, rather than just relying on the drug alone.

GLP-1 receptor agonists (specifically liraglutide, semaglutide, and tirzepatide) are primarily utilized in clinical practice for obesity treatment rather than type 2 diabetes, with obesity being the dominant indication across these agents.

If you are using GLP-1 medications like Ozempic, Wegovy, or Mounjaro, you are part of a large group using them primarily for weight management, not just blood sugar control. If you dislike injections, ask about oral semaglutide. Be aware that newer drugs like Tirzepatide may be expensive and not covered by insurance, which can lead to stopping treatment early.

Oral semaglutide is increasingly preferred by younger female patients with fewer comorbidities compared to subcutaneous semaglutide.

If you are a younger woman with few other health issues, you might be more likely to be prescribed oral semaglutide. This form is taken daily as a pill, which some patients prefer over weekly injections. Ensure you follow the specific administration instructions for oral semaglutide (taken on an empty stomach with water) to ensure effectiveness.

Abnormal adiposity is the dominant causal driver of cardiometabolic disease, and targeting it as the primary intervention simplifies management and reduces the need for concurrent pharmacotherapy for downstream drivers like hypertension and dyslipidemia.

Focus on weight loss as the primary treatment for high blood pressure, high blood sugar, and high cholesterol. Instead of taking multiple medications for each issue, prioritize lifestyle changes or weight-loss medications to reduce body fat, as this addresses the root cause that drives all other metabolic risks.

Glucagon receptor agonism (GCGRA), particularly in triagonists like retatrutide, increases energy expenditure and enhances weight loss efficacy compared to GLP-1/GIP agonists alone, though it carries risks of adverse events like tachycardia.

Triagonist medications (combining GLP-1, GIP, and Glucagon effects) can achieve higher weight loss (up to 24%) than current GLP-1 drugs by actively increasing how many calories you burn, not just by reducing appetite. While these drugs can cause side effects like rapid heart rate, doctors can manage this by starting with very low doses and increasing them slowly. This approach offers a more sustainable path to weight loss by counteracting the body's tendency to slow down metabolism.

Lean MASLD (normal BMI but with metabolic dysfunction) is a distinct phenotype driven by sarcopenia, adverse fat distribution, and genetic susceptibility, requiring different treatment strategies than obesity-driven MASLD.

If you have a normal BMI but metabolic issues (like high blood sugar or blood pressure), you can still develop fatty liver disease. This 'lean MASLD' is often linked to low muscle mass and genetics. Focus on building muscle and managing metabolic health rather than just losing weight.

Baseline diet quality in weight loss trial participants is characterized by high saturated fat intake (median 12.1% of energy) and low dietary fiber (median 17.0 g/day), indicating a need for interventions to prioritize diet quality over simple energy restriction.

If you are trying to lose weight, do not just count calories or cut fat. Look at what kind of fat and carbs you are eating. Your baseline diet likely has too much saturated fat and not enough fiber. To improve your health outcomes, especially for heart disease and diabetes risk, you must improve the quality of your diet (more fiber, better fats) alongside any weight loss efforts.

Black race and younger age are significantly associated with lower diet quality scores (AHEI-2010 and DASH) in this population, highlighting racial disparities in baseline diet quality.

If you are Black or younger, you may face specific challenges in maintaining a high-quality diet. The study shows these groups often have lower diet quality scores. Interventions should be tailored to address these specific disparities, such as improving access to healthy foods and culturally relevant nutrition education.

Metabolic surgery (specifically Roux-en-Y Gastric Bypass and Sleeve Gastrectomy) yields significantly higher diabetes remission rates compared to intensive lifestyle interventions or medical therapy alone.

For eligible patients (BMI >= 35, or >= 27 with comorbidities), metabolic surgery (RYGB or Sleeve Gastrectomy) offers the highest chance of type 2 diabetes remission, significantly outperforming lifestyle changes or medication alone. While upfront costs and surgical risks exist, laparoscopic techniques have made it safer, and it reduces long-term healthcare costs by resolving other obesity-related conditions. Early intervention (shorter diabetes duration) improves success rates.

Dietary weight loss interventions result in a consistent percentage of lean mass loss (approximately 29-30%) regardless of the total magnitude of weight lost, provided the loss exceeds 5% of baseline body weight.

If you lose weight through diet, expect to lose about 30% of that weight as lean mass, regardless of whether you lose 5% or 15% of your body weight. This is a consistent biological response to caloric restriction, not a failure of your diet. To mitigate this, incorporate resistance training, as the paper notes this is a benchmark for 'dietary modifications' without medication.

Dietary weight loss stabilizes the proportion of lean mass lost (%LML) at approximately 25-33% once total weight loss exceeds 5%, contradicting the hypothesis that lean loss increases proportionally with greater weight loss.

When you lose weight through diet, you will lose some muscle along with fat. This is normal and accounts for about 25-33% of the total weight lost, regardless of how much weight you lose. Men tend to lose a slightly higher percentage of lean mass than women. To minimize this, combine your diet with resistance training and adequate protein intake, but do not fear that larger weight loss equals disproportionately larger muscle loss.

Diet-based weight loss interventions result in minimal loss of appendicular lean soft tissue (a surrogate for skeletal muscle), with losses accounting for less than 10% of total mass loss after adjusting for fat-free adipose tissue.

If you are losing weight through diet alone (without resistance training), you will not lose significant muscle mass. The study found that lean tissue loss was minimal (less than 10% of total weight lost) and that your muscle mass relative to your new body size actually increased. You do not need to fear muscle loss as a barrier to starting a diet.

Total daily energy expenditure (TDEE) declines significantly with age in both males and females, primarily driven by reductions in fat-free mass and increases in fat mass, with the most substantial drop occurring during the transition from middle age to older adulthood.

Your daily calorie needs drop as you age, especially after 55. This isn't just 'hormones'; it's largely because you lose muscle (fat-free mass) and gain fat. To maintain your weight, you must adjust your caloric intake or increase activity to match this lower expenditure. Focus on preserving muscle mass through resistance training to keep your metabolic rate higher.